Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

ABSTRACT:

SUBMITTER: Munro APS 

PROVIDER: S-EPMC9084623 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature